Table 2.

Any-grade and grade ≥ 3 AEs and investigator-reported AEs

	H SC + P IV + D IV (N = 412)
	Any grade	Grade ≥ 3
AE
Leukopenia	29 (7.0)	15 (3.6)
Febrile neutropenia	35 (8.5)	35 (8.5)
Neutropenia	75 (18.2)	52 (12.6)
Diarrhea	261 (63.3)	21 (5.1)
Mucositis	68 (16.5)	3 (0.7)
Interstitial lung disease	5 (1.2)	1 (0.2)
Rash	68 (16.5)	4 (1.0)
Hypersensitivity, anaphylaxis	1 (0.2)	1 (0.2)
Investigator-reported AE
ARR and local injection site reactions	87 (21.1)	5 (1.2)
ARR and local injection site reactions: Only H SC-related	21 (5.1)	0
ARR and local infusion site reactions: Only P IV infusion-related	22 (5.3)	1 (0.2)
ARR and local infusion site reactions: Only D IV infusion-related	48 (11.7)	4 (1.0)

AE adverse event, ARR administration-related reactions, D IV intravenous docetaxel, H SC subcutaneous trastuzumab, P IV intravenous pertuzumab

Data are number of patients (%)